IL226377B - Nanoparticle isoflavone compositions & methods of making and using the same - Google Patents

Nanoparticle isoflavone compositions & methods of making and using the same

Info

Publication number
IL226377B
IL226377B IL226377A IL22637713A IL226377B IL 226377 B IL226377 B IL 226377B IL 226377 A IL226377 A IL 226377A IL 22637713 A IL22637713 A IL 22637713A IL 226377 B IL226377 B IL 226377B
Authority
IL
Israel
Prior art keywords
preparations
preparation
methods
isoflavone nanoparticles
isoflavone
Prior art date
Application number
IL226377A
Other languages
English (en)
Hebrew (he)
Other versions
IL226377A0 (en
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Publication of IL226377A0 publication Critical patent/IL226377A0/en
Publication of IL226377B publication Critical patent/IL226377B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
IL226377A 2010-11-15 2013-05-16 Nanoparticle isoflavone compositions & methods of making and using the same IL226377B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/946,711 US8900635B2 (en) 2010-11-15 2010-11-15 Nanoparticle isoflavone compositions and methods of making and using the same
PCT/US2011/060829 WO2012068140A1 (en) 2010-11-15 2011-11-15 Nanoparticle isoflavone compositions & methods of making and using the same

Publications (2)

Publication Number Publication Date
IL226377A0 IL226377A0 (en) 2013-07-31
IL226377B true IL226377B (en) 2019-09-26

Family

ID=46047969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226377A IL226377B (en) 2010-11-15 2013-05-16 Nanoparticle isoflavone compositions & methods of making and using the same

Country Status (6)

Country Link
US (9) US8900635B2 (enExample)
EP (1) EP2640188B1 (enExample)
JP (3) JP2013545752A (enExample)
CA (1) CA2852410C (enExample)
IL (1) IL226377B (enExample)
WO (1) WO2012068140A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
US9623004B2 (en) 2013-08-02 2017-04-18 Humanetics Corporation Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
US9084726B2 (en) * 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
US20170000761A1 (en) * 2013-11-27 2017-01-05 Humanetics Corporation Protecting tissue and mitigating injury from chemical exposure
TWI583404B (zh) * 2015-07-13 2017-05-21 高雄醫學大學 ７,３’,４’-大豆異黃酮製劑的製備方法
WO2018156946A1 (en) * 2017-02-24 2018-08-30 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
US20220193103A1 (en) * 2019-04-23 2022-06-23 The University Of North Carolina At Chapel Hill Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model
WO2021207176A1 (en) * 2020-04-06 2021-10-14 Humanetics Corporation Genistein treatment of inflammatory pulmonary injury
CA3195195A1 (en) * 2020-10-16 2022-05-27 Humanetics Corporation Solid dispersion genistein compositions and methods of making and using the same
US20240058299A1 (en) * 2021-01-11 2024-02-22 Humanetics Corporation Genistein treatment of inflammatory and immunological disorders
CN112843048A (zh) * 2021-04-01 2021-05-28 郑州新泽生物科技有限公司 一种用于抑制雄性动物发情的液体制剂及其制备方法
CN113080365B (zh) * 2021-04-02 2022-12-06 嘉应学院 一种大豆素纳米粉的制备方法及其应用
WO2023177676A1 (en) * 2022-03-14 2023-09-21 University Of South Florida Genistein for asthma treatment
WO2023212130A1 (en) 2022-04-28 2023-11-02 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids
CN114948869A (zh) * 2022-05-26 2022-08-30 中国药科大学 一种染料木素纳米混悬液的制备方法及该方法制备的染料木素纳米混悬液
WO2025117337A1 (en) 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390559A (en) 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
JP2001309764A (ja) 2000-05-01 2001-11-06 Taiyo Kagaku Co Ltd ポリフェノール類組成物
US7655694B2 (en) 2000-06-14 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
ES2254725T3 (es) 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
AU2003298659A1 (en) 2002-11-15 2004-06-15 Cargill, Incorporated Soluble isoflavone compositions
WO2005033279A2 (en) 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
BRPI0512829A (pt) 2004-07-01 2008-04-08 Warner Lambert Co preparação de composições farmacêuticas contendo nanopartìculas
EP1802279A1 (en) 2004-09-29 2007-07-04 Michael Ary Bos Caratenoid composition and method for preparation thereof
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EA015336B1 (ru) 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Стабильная композиция с наночастицами ацетаминофена
US8685456B2 (en) * 2005-06-29 2014-04-01 Dsm Ip Assets B.V. Topical compositions comprising nanoparticles of an isoflavone
WO2007000193A1 (en) * 2005-06-29 2007-01-04 Dsm Ip Assets B.V. Isoflavone nanoparticles and use thereof
US9743680B2 (en) 2005-10-14 2017-08-29 Wild Flavors, Inc. Microemulsions for use in food and beverage products
US8353639B2 (en) * 2005-11-18 2013-01-15 Deere & Company Turnbuckle lock
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2008086400A2 (en) * 2007-01-09 2008-07-17 Isp Investments Inc. Sirtuin-activating compounds of enhanced bioavailability
JP2009067752A (ja) 2007-09-14 2009-04-02 Akuto Kk 製剤の製造方法及び製剤
EP2349237A4 (en) 2008-07-31 2012-07-25 Santosh Kumar Kar CURCUMIN NANOTEILS AND MANUFACTURING METHOD THEREFOR
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
AU2011265184B2 (en) 2010-06-11 2016-08-04 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
JP5948871B2 (ja) 2011-12-28 2016-07-06 株式会社東洋新薬 ポリフェノール含有組成物
US9084726B2 (en) 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same

Also Published As

Publication number Publication date
US8551530B2 (en) 2013-10-08
US20170304258A1 (en) 2017-10-26
US20190160038A1 (en) 2019-05-30
US9308167B2 (en) 2016-04-12
US20220370403A1 (en) 2022-11-24
US10039739B2 (en) 2018-08-07
US20150050357A1 (en) 2015-02-19
JP2013545752A (ja) 2013-12-26
US10729674B2 (en) 2020-08-04
US20160374984A1 (en) 2016-12-29
US9724325B2 (en) 2017-08-08
US9636322B2 (en) 2017-05-02
EP2640188A1 (en) 2013-09-25
US20120164190A1 (en) 2012-06-28
US20210000788A1 (en) 2021-01-07
EP2640188B1 (en) 2021-01-06
US20160175276A1 (en) 2016-06-23
CA2852410A1 (en) 2012-05-24
US8900635B2 (en) 2014-12-02
US20120121654A1 (en) 2012-05-17
EP2640188A4 (en) 2014-04-23
IL226377A0 (en) 2013-07-31
CA2852410C (en) 2020-06-30
JP2016074683A (ja) 2016-05-12
JP6181733B2 (ja) 2017-08-16
WO2012068140A1 (en) 2012-05-24
JP2018008967A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
IL226377B (en) Nanoparticle isoflavone compositions & methods of making and using the same
IL280819A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
IL280771A (en) Lipid nanoparticle compositions and methods for mrna delivery
SG10201602752XA (en) Melanin modification compositions and methods of use
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
IL229663A0 (en) Algal lipid compositions and methods of preparing and utilizing same
PL2552959T3 (pl) Przeciwciała przeciwko MUC16 i metody stosowania
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
EP2787985A4 (en) BIOCIDAL COMPOSITION AND METHODS OF USE
IL223725B (en) Formulations of rifaximin and uses thereof
HUE042011T2 (hu) Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
HRP20190080T1 (hr) Postupak i formulacija za inhaliranje
EP2536283B8 (en) Phenyl-heteroaryl derivatives and methods of use thereof
PT2683731T (pt) Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
PL2601105T3 (pl) Sposób i system przygotowania fiolki
IL230855A0 (en) Cabazitaxel formulations and methods for their preparation
IL229963A0 (en) Substituted quinolines and their use as medicaments
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
IL225262A0 (en) Methods and compositions for treating lung cancer
EP2798063A4 (en) PRODUCTION OF DIHYDROSTERCULIC ACID AND ITS DERIVATIVES
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
IL229631A0 (en) Test of lysyl oxidase-like 2 and methods of using it
EP2742033A4 (en) FLAVONOID COMPOUNDS AND METHODS OF USE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed